3 Stories Of Pharma Outsourcing: Wellstat Therapeutics, Ramsey Lake, And Flexion

The U.S. Food & Drug Administration approved 45 new drugs in 2015, a 20-year high. Thirty-three of them are small molecules—the products of chemical synthesis.

One of the new drugs is Xuriden, a small molecule from Wellstat Therapeutics that treats an ultrarare disease called hereditary orotic aciduria. By the time Xuriden was approved last September, Wellstat had been working with its active ingredient, uridine triacetate, for close to 15 years.

Back to news